Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference
13 8월 2020 - 5:01AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that company management will
participate in the 1-on-1 meetings at the upcoming Needham Virtual
Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis® ImmunoID NeXT Platform®
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200812005619/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com 415-202-5678
Media Contact: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024